STOCK TITAN

Roivant Sciences Ltd - ROIV STOCK NEWS

Welcome to our dedicated news page for Roivant Sciences (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roivant Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roivant Sciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.43%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
-
Rhea-AI Summary
Roivant and Pfizer announce collaboration to develop and commercialize RVT-3101, a potential first-in-class monoclonal antibody targeting TL1A for inflammatory bowel disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.21%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
Roivant Sciences Ltd

Nasdaq:ROIV

ROIV Rankings

ROIV Stock Data

8.82B
423.13M
20.63%
62.12%
3.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
UK
London

About ROIV

roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak